skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Hi Team,
This may be a bit of a "shot in the dark" question, but what i'd like to know is your top 5 companies with a "high risk - high reward" profile and 5 in the "medium risk - high reward" for a 3-5 year hold.
thanks
michele
Read Answer Asked by Michele on February 13, 2020
Q: Hi Peter,
Do you agree that since around October 2019 CGY's share price chart seems to show strong momentum with good share price increases along with increasing volume especially this February? I used to own CGY some years ago for the dividend but found the share price stable...not many drops and few increases and sold the stock. I characterized the stock then as an income stock which I think agrees with your analysis. Do you feel anything has changed at CGY's operations or company management since October 2019 to have caused the stock to act more like a momentum company? You have noted in previous questions that their debt is higher but the dividend has not been increased and the share count is unchanged. Am I to understand they are borrowing more money to invest in their business and would that this growth in business be the cause of the better momentum? Their business seems to be related to satellites so would you consider CGY to be a high tech company?
Thanks for all your help.
Jim
Read Answer Asked by James on February 12, 2020
Q: I’m curious as to why MCR is selling off today. There was news today that the estimated cost of the TMX line has nearly doubled. With macro’s spread being reimbursable (one of the few with out a cap from my understanding), wouldn’t this be very positive? (Ie. macro stands to make more then original contract estimates). Is this not one of the cheapest stocks on the Canadian stock exchange based on p/e? Thanks
Read Answer Asked by Scott on February 11, 2020
Q: I'd appreciate your take on Premier Health which no analyst seems to cover. I discovered it while searching for other publicly-traded companies that use OSCAR as a platform for their electronic medical record (EMR) offerings.

WELL Health has been very clear that they are in the hunt for OSCAR-related assets - it so happens that PHGI has three of them (JunoEMR, KindredEHR and ClinicAid). They also have a couple of other assets that WELL would like to have or planning to develop (e.g. 4 clinics, a patient portal, telemedicine, a medical billing app, 2 pharmacies, interactive kiosks, etc.).
Read Answer Asked by Richard on February 10, 2020
Q: In your Feb 7 response to Jerry on PRN after referring to recent strong momentum you say “markets obviously think there is potential here, but the company now needs to start delivering on that potential.”

I would argue that PRN started delivering on the potential long ago – the company received FDA approval Aug 2019 after a successful clinical trial; PRN successfully listed on NASDAQ last fall; the company announced in early January this year a deal and partnership with RadNet, the largest network of outpatient imaging centres in the US; and recently PRN raised US$ 40 million in an equity financing and retired all bank debt ahead of schedule. PRN is now well positioned to scale the business without further dilution.

I recognize there remains commercialization risk and there is reimbursement risk and revenues are essentially non-existent at this early stage but what we have here is a very experienced very competent management team that has done it before with NOVADAQ. Significantly, the CEO Arun and his team are not doing this because they need to money. They will not rush it they will do it right. I think you have mentioned in the past that this is one of the best small cap situations to invest in – assuming you can deal with the volatility and risk.
Read Answer Asked by James on February 09, 2020
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!